How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-obstructive-pulmonary-disease-with-bronchospasms.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic Obstructive Pulmonary Disease with Bronchospasms — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic Obstructive Pulmonary Disease with Bronchospasms (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic Obstructive Pulmonary Disease with Bronchospasms, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Spiriva	TIOTROPIUM BROMIDE	Boehringer Ingelheim	Anticholinergic	Muscarinic acetylcholine receptor M3	2004-01-01
ProAir	albuterol	Generic (originally Allen & Hanburys/GSK)	SABA (Short-acting beta-2 agonist)	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-2 adrenergic receptor	1982-05-05
Proventil	salbutamol	Merck & Co.	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	1981-01-01
Theophyllin	Theophyllin	University of Bergen		Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1
Aminophyllin	Aminophyllin	University of Padova		Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Chronic Obstructive Pulmonary Disease with Bronchospasms
Boehringer Ingelheim · 1 drug in Chronic Obstructive Pulmonary Disease with Bronchospasms
Generic (originally Allen & Hanburys/GSK) · 1 drug in Chronic Obstructive Pulmonary Disease with Bronchospasms
Merck & Co. · 1 drug in Chronic Obstructive Pulmonary Disease with Bronchospasms
University of Bergen · 1 drug in Chronic Obstructive Pulmonary Disease with Bronchospasms
University of Padova · 1 drug in Chronic Obstructive Pulmonary Disease with Bronchospasms

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic Obstructive Pulmonary Disease with Bronchospasms:

Cite this brief

Drug Landscape (2026). Chronic Obstructive Pulmonary Disease with Bronchospasms — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-obstructive-pulmonary-disease-with-bronchospasms. Accessed 2026-06-10.

Chronic Obstructive Pulmonary Disease with Bronchospasms full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing